Dr. Pavlick on Immunotherapy Clinical Trials in Basal and Squamous Cell Carcinomas

Anna C. Pavlick, DO
Published: Tuesday, Dec 20, 2016



Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma of the skin.

Frontline therapy for patients with basal cell carcinoma are hedgehog inhibitors, Pavlick explains. However, similar to the targeted therapies available for patients with melanoma, most patients do become resistant to these therapies. Therefore, since these patients are not chemotherapy-sensitive or radiation therapy-sensitive, a clinical trial is opening in the near future that will explore treatment with immunotherapy for those who fail on hedgehog inhibitors. If the results are promising, this could lead to a new frontline treatment option for these individuals.

Similar to squamous cell skin cancer, Pavlick says there is another clinical trial opening that will explore immunotherapy in this patient population, as well. This would be practice changing for the field, she explains.
SELECTED
LANGUAGE


Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma of the skin.

Frontline therapy for patients with basal cell carcinoma are hedgehog inhibitors, Pavlick explains. However, similar to the targeted therapies available for patients with melanoma, most patients do become resistant to these therapies. Therefore, since these patients are not chemotherapy-sensitive or radiation therapy-sensitive, a clinical trial is opening in the near future that will explore treatment with immunotherapy for those who fail on hedgehog inhibitors. If the results are promising, this could lead to a new frontline treatment option for these individuals.

Similar to squamous cell skin cancer, Pavlick says there is another clinical trial opening that will explore immunotherapy in this patient population, as well. This would be practice changing for the field, she explains.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x